PF-06826647 is a TYK2-selective kinase inhibitor which binds to the catalytically active JH1 kinase domain, in contrast to BMS-986165, a TYK2 inhibitor in Ph. III for psoriasis that binds to the JH2 pseudokinase domain. TYK2-selective inhibitors are expected to have anti-inflammatory activity with reduced side effects such as anemia due to [...]
< 1 minute read
Sep. 18, 2021
PF-06826647: A TYK2-Selective Kinase Inhibitor
PF-06826647
TYK2-selective kinase inhibitor (JH1 domain) in Ph. II for inflamm. conditions (oral, QD) from structure-based design J. Med. Chem., Aug. 5, 2020 Pfizer, Cambridge, MA / Groton, CT
Loading...
